| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
In xenografted BALB/c-nu/nu mice that were subcutaneously injected the FLAG-tagged CD109 overexpressing cells, CD109 secreted from inoculated tumors was detected in sera, using western blotting and CD109 ELISA. Concentrations of tumor-secreted CD109 increased proportionally as tumors enlarged. These results indicate that CD109 is present in serum as a soluble form, and suggest its potential as a novel tumor marker in patients with cancers that express CD109.
In clinical experiment, concentration of CD109 in sera that were from oral cancer patients including precancerous lesion was measured using CD109 ELISA. The result did not reflect the tumor size dependent manner that was shown in xenografted mice.
|
